This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TORC resTORbio (TORC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About resTORbio Stock (NASDAQ:TORC) 30 days 90 days 365 days Advanced Chart Get resTORbio alerts:Sign Up Key Stats Today's Range$0.60▼$0.6350-Day Range$2.28▼$14.7752-Week Range$0.86▼$10.50Volume363,835 shsAverage Volume1.15 million shsMarket Capitalization$22.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. Read More Receive TORC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for resTORbio and its competitors with MarketBeat's FREE daily newsletter. Email Address TORC Stock News HeadlinesAdicet Bio Inc (ACET)January 30, 2024 | investing.comMichelle Chaka Joins Torc as Senior Vice President, Safety and RegulatoryFebruary 24, 2023 | finance.yahoo.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 3 at 2:00 AM | American Alternative (Ad)TinOne Resources Inc. (TORC.V)January 10, 2023 | finance.yahoo.comCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - ForbesSeptember 19, 2022 | forbes.comFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business JournalsSeptember 12, 2022 | bizjournals.comForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comJuly 8, 2022 | streetinsider.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comJune 21, 2022 | gurufocus.comSee More Headlines TORC Stock Analysis - Frequently Asked Questions How were resTORbio's earnings last quarter? resTORbio, Inc. (NASDAQ:TORC) issued its quarterly earnings data on Thursday, July, 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. When did resTORbio IPO? resTORbio (TORC) raised $86 million in an IPO on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of resTORbio own? Based on aggregate information from My MarketBeat watchlists, some other companies that resTORbio investors own include Novavax (NVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings7/30/2020Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TORC CIK1720580 Webwww.restorbio.com Phone(857) 315-5521FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-78.12% Return on Assets-71.63% Debt Debt-to-Equity RatioN/A Current Ratio20.69 Quick Ratio20.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book0.27Miscellaneous Outstanding Shares36,454,000Free FloatN/AMarket Cap$22.28 million OptionableNot Optionable Beta2.43 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:TORC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TORC Stock Alerts